je.st
news
Tag: medivir
Notice of Annual General Meeting of Medivir AB
2016-03-31 20:03:44| Appliances - Topix.net
The shareholders in Medivir AB are hereby summoned to the annual general meeting on Tuesday 3 May 2016 at 2 p.m. at the conference center 7A Centralen, Vasagatan 7, Stockholm. Shareholders who wish to participate in the meeting must be recorded in the share register maintained by Euroclear Sweden AB on Wednesday 27 April 2016, and , notify the company of their intention participate in the meeting not later than on Wednesday 27 April 2016 in writing to Medivir AB, Blasieholmsgatan 2, SE-111 48 Stockholm, Sweden.
Tags: general
notice
meeting
annual
Medivir Announces That Janssen Has Started a Phase IIa Study to...
2015-10-16 18:07:48| Appliances - Topix.net
Medivir AB today announces that Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies , has started a phase IIa clinical trial to evaluate the combination of simeprevir, odalasvir , and AL-335 in treatment-nai 1 2ve patients with genotype 1 chronic hepatitis C virus infection. This phase IIa study is a randomized, open-label, three-arm study of AL-335, a nucleotide-based HCV NS5B polymerase inhibitor, odalasvir, an HCV NS5A inhibitor and simeprevir, an HCV NS3/4A protease inhibitor.
Medivir to merge Research and Development and implement changes within the management group
2015-09-16 18:44:20| Appliances - Topix.net
The new unit will span the entire process, from the early research to the late-stage development phases. This change will both increase Medivir's ability to prioritise and enhance efficiency within its research operations and expand the flexibility and readiness for a broadening of the development portfolio.
Tags: the
within
group
research
Medivir announces that Janssen has started a phase I study to...
2015-08-03 17:02:50| Appliances - Topix.net
Medivir AB today announces that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has started a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir , on the pharmacokinetics of AL-335 in healthy volunteers. This phase I study is an open-label, two-group study of simeprevir, odalasvir, a hepatitis C virus NS5A inhibitor, and of AL-335, a nucleotide-based HCV polymerase inhibitor.
Medivir: OLYSIO sales during the second quarter 2015
2015-07-14 18:02:01| Appliances - Topix.net
Medivir AB announces that the global second quarter net sales of OLYSIOA amounted to 264 MUSD, of which 50 MUSD were sales in the USA. The royalty for the second quarter amounted to 166 MSEK .